# Medicare Just Made GLP-1 Drugs Affordable for 14 Million Seniors
Medicare has capped copayments for GLP-1 drugs at $35 per month for beneficiaries with Type 2 diabetes, opening access to medications like Ozempic and Wegovy for approximately 14 million eligible seniors.
This shift comes as GLP-1 receptor agonists have transformed diabetes and weight management treatment. These drugs work by mimicking hormones that regulate blood sugar and appetite. The monthly cap applies to Part D prescription drug coverage, making these previously expensive medications accessible to more older adults.
The $35 copay represents a dramatic decrease from typical out-of-pocket costs. Ozempic and similar GLP-1 medications often cost several hundred dollars monthly without insurance coverage. For seniors on fixed incomes, this price barrier has prevented many from accessing treatments their doctors recommended.
Eligibility depends on Medicare Part D coverage status. Seniors currently enrolled in Part D plans automatically benefit from the cap. Those with Original Medicare who don't have prescription drug coverage can enroll during the annual open enrollment period, which runs October 15 to December 7.
Doctors emphasize that GLP-1s work best alongside lifestyle changes. Diet modifications, regular physical activity, and weight management remain foundational for Type 2 diabetes control. These medications enhance but don't replace those habits.
The change addresses a healthcare equity issue. Wealthier seniors have accessed GLP-1s while lower-income beneficiaries couldn't afford them, widening health disparities among older Americans. Now cost no longer prevents qualified seniors from starting these evidence-based treatments.
Medicare recipients should contact their plan providers to confirm coverage details. Some plans may require prior authorization or have formulary restrictions. Your doctor can help navigate coverage questions and determine whether a GLP-1 medication